Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

By E. Boersma, Robert A. Harrington, D. Moliterno, Harvey D. White, P. Théroux, Frans Van de Werf, A. de Torbal, P. Armstrong, L. Wallentin, R. Wilcox and 4 more. The Lancet, 2002

1,005 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Surgery

View Paper: https://www.semanticscholar.org/paper/ad5a04b7b045cd9fdb48d1dde9a65e137efdf7fc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Robert M. Califf
2. Joseph S. Alpert
3. Judith Hochman

In Surgery

1. Klaus Ley
2. Robert M. Califf
3. Joseph S. Alpert
4. Judith Hochman

Citations in the corpus

• Platelet-neutrophil-interactions: linking hemostasis and inflammation. (2007, background): “In contrast to this recommendation, there is no consensus on the application of GPIIa/IIIb inhibitors for patients who are not scheduled for early revascularization.(137,138) Oral long-term treatment with GIIb/IIIa inhibitors is not more effective than aspirin or, when combined with aspirin, is not ”